Embraer Shares See Volume, Co. Granted U.S. Patent Titled ‘VERTICAL TAKE-OFF AND LANDING (VTOL) AIRCRAFT WITH ROTOR CONFIGURATIONS TOLERANT TO ROTOR FAILURE’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=11383830&OS=11383830&RS=11383830
Athenex Receives Notice Of Allowance For U.S. Patent Titled ‘METHODS OF TREATING AND/OR PREVENTING ACTINIC KERATOSI’
https://patentcenter.uspto.gov/#!/applications/16804092/ifw/docs
Adverum Biotechnologies Presents Best-Corrected Visual Acuity And Central Subfield Thickness Analyses After Single IVT Injection Of ADVM-022 (Ixo-vec) In OPTIC Study In Wet AMD
Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD
- Study participants had
NexImmune Shares Soar Following FDA’s Clearance To Initial-Stage HPV Cancer Study
NexImmune, Inc. (NASDAQ: NEXI) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for its first cellular therapy product candidate NEXI-003 addressing solid tumors.
Omega Therapeutics Gets FDA Nod For Initial-Stage Liver Cancer Study
The U.S. Food and Drug Administration (FDA) has announced clearance to Omega Therapeutics’ (NASDAQ: OMGA) Investigational New Drug (IND) to initiate a Phase 1/2 clinical study of its candidate OTX-2002 for the treatment of hepatocellular carcinoma (HCC).
NexImmune Announces IND Clearance By US FDA For NEXI-003 For Treatment Of HPV-Related Cancers
First IND for NexImmune's AIM nanoparticle platform in solid tumors
IND clearance enables commencement of a clinical trial to evaluate NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), in
Oncternal Therapeutics Announces Clinical Trial Collaboration To Advance Zilovertamab Phase 3 Study In Combination With Ibrutinib For Patients With MCL
Clinical trial collaboration supports global registrational Phase 3 study ZILO-301, to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinib
Agreement is supportive of the planned initiation